Peloton Therapeutics, Inc. announced the appointment of Mohammad Hirmand, M.D., as Chief Medical Officer. Dr. Hirmand will assume his new role on the executive management team on May 1, 2017 and will lead the company’s clinical drug development forward. Dr. Hirmand most recently served as Chief Medical Officer at Medivation, where he played a vital role in advancing XTANDI (enzalutamide) through clinical trials that led to its approval by the U.S. Food and Drug Administration for the treatment of metastatic castration-resistant prostate cancer. His responsibilities also included the in-licensing and global clinical development of the poly ADP ribose polymerase inhibitor, talazoparib. Before Medivation, he was Senior Director of Clinical Development at Nuvelo, Inc., where he led the Clinical Operations, Clinical Data Management and Clinical Sciences/Medical Monitor staff. Prior to that, he served as Director of Oncology Development at SuperGen, Inc. and as Associate Director of Clinical Research at Amgen, Inc., where he led clinical development efforts for Tularik's oncology trials.